Enfusion, Inc. (NYSE:ENFN) Q4 2022 Results Conference Call March 7, 2023 8:30 AM ET
Company Participants
Ignatius Njoku - Head, IR
Oleg Movchan - CEO
Brad Herring - CFO
Conference Call Participants
James Faucette - Morgan Stanley
Kevin McVeigh - Credit Suisse
Dylan Becker - William Blair
Koji Ikeda - Bank of America
Matthew Kikkert - Stifel
Operator
Good morning, ladies and gentlemen and thank you for standing by. Welcome to Enfusion's Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to hand you over to our host Ignatius Njoku, Head of Investor Relations. Please go ahead.
Ignatius Njoku
Good morning and thank you operator. We welcome you to Enfusion's fourth quarter 2022 earnings conference call. Hosting today's call are Oleg Movchan, Enfusion's Chief Executive Officer; and Brad Herring, Enfusion's Chief Financial Officer.
Please note, our quarterly shareholder letter, which includes our quarterly financial results of all been posted to our IR website. I'd like to remind you that today's call may contain forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including those set forth in our filings with the SEC and are available in the Investor Relations section in our website. Actual results may differ materially from any forward-looking statements we make today.
These forward-looking statements speak only as of today, and the company does not assume any obligation or intent to update them following today's call, except as required by law. In addition, today's call may include non-GAAP measures. These measures should be considered as a supplement to and not as a substitute for GAAP financial measures. Reconciliation to the nearest GAAP measure can be found in today's quarterly shareholder letter, which is available on the company's website.
With that, I'd like to turn the call over to Oleg to begin.
Oleg Movchan
Good morning, and thank you all for joining us today to discuss our fourth quarter 2022 results. I'm happy to be here and I'm honored to be addressing you today formal and CEO. I would like to first thank all of my colleagues for the warm welcome that I received in this new role. I'm looking forward to lead in Enfusion and I'm energized by the opportunity to set that Enfusion is facing today. I'm also thrilled to welcome Brad Herring as our Chief Financial Officer, who brings along an impressive track record as a public company CFO. I look forward to working with him to position Enfusion for scale as we go through the next stage of our growth.